| |
|
Form Serial Number: |
DA20260914E00536
|
| 1.
Date of relevant event: |
30/08/2026
(dd/mm/yyyy)
|
| 2.
Date when director became aware of the relevant event/ interest in the shares (if later): |
09/09/2026
(dd/mm/yyyy)
|
| 3.
Stock code: |
02496 |
| 4.
Name of listed corporation: |
武漢友芝友生物製藥股份有限公司 - B - H股 |
| 5.
Class of shares: |
Domestic Shares |
| 6.
Number of issued shares in class: |
14,370,087 |
| 7.
Name of director (English) as printed on HKID Card/Passport: |
| (Surname) |
YUAN |
| (Other names) |
QIAN |
|
|
|
| 10.
Name of director (Chinese): |
袁謙 |
| 11.
Chinese Character Code as printed on HKID Card: |
|
| |
| 24.
Details of relevant event: |
|
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Consideration code
|
| Long position |
| 1101 | The number of shares in which you are interested has increased because:
you purchased the shares |
|
|
|
35,592,400 |
CNY |
|
|
2.4300 |
|
| Short position |
|
|
|
|
|
|
|
|
|
| |
|
| 25.
Total shares in listed corporation immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 0 | 0.00 |
|
| |
| 26.
Total shares in listed corporation immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 35,592,400 | 247.68 |
|
| |
| 27.
Capacity in which interests disclosed in Box 26 are held: |
| Code describing capacity | Number of shares |
| |
| 2103 | Interests held jointly with another person |
| |
|
| |
| 28.
Further information in derivative interests in listed corporation : |
| Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
| | | | | | | | | | | |
|
| |
| 29.
Further information in relation to interests of children under 18 and/or spouse: |
| Child/Spouse | Name of child/spouse | Number of shares |
| | |
|
| |
| 30.
Further information in relation to interests of corporations controlled by Director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| | | | | |
|
| |
| 31.
Further information in relation to interests held by Director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| ZHOU PENGFEI | Addresses of individuals are not displayed. | |
| 周宏峰 | Addresses of individuals are not displayed. | |
| 武漢才智投資管理合夥企業(有限合夥) | Addresses of individuals are not displayed. | |
|
| |
| 32.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
| Names of Trust | Address | Status code | Number of shares |
| | | |
|
| |
| 33.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
| Names of other parties | Address | Number of shares |
| | |
| Total number of shares in which a director is interested under sections 317 and 318 | |
|
| |
| 34.
Supplementary information: |
根據袁謙、周宏峰、ZHOU PENGFEI及武漢才智投資管理合夥企業(有限合夥)(「武漢才智」)(共同及各自為「一致行動人士」)於2018年6月30日訂立的一致行動人士協議及一致行動人士訂立的日期為2020年10月26日及2023年6月2日的一致行動人士補充協議，一致行動人士同意(i)就提呈武漢友芝友生物製藥股份有限公司(「本公司」)所有股東大會及董事會表決的有關本公司及其附屬公司日常管理及營運的議案達成共識，從而一致行動；及(ii)在無法達成共識時，各一致行動人士就議案作出的表決應與袁謙一致，或若袁謙缺席表決時，一致行動人士作出的表決應與在會議上投票的一致行動人士中股權比例最高的其中一名一致行動人士一致。有關方格24而言，於2026年8月30日，本公司與袁謙、周宏峰及ZHOU PENGFEI(「認購方」)訂立股份認購協議，據此，認購方有條件同意認購，而本公司有條件同意按每股內資股人民幣2.43元的認購價配發及發行合共35,592,400股內資股。有關股份認購協議的詳情，請參閱本公司於2026年9月9日發出的公告。
|
| 35.
Log/Serial Number of the previous form: |
|
| 36.
Number of concert party document(s) under section 317 attached/uploaded: |
|
|
Date of filing this Form 3A: |
14/09/2026
(dd/mm/yyyy)
|
| |